232 related articles for article (PubMed ID: 9352130)
1. Prostate-specific antigen (protein and mRNA) analysis in the differential diagnosis and staging of prostate cancer.
Castaldo G; Cecere G; di Fusco V; Prezioso D; d'Armiento M; Salvatore F
Clin Chim Acta; 1997 Sep; 265(1):65-76. PubMed ID: 9352130
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
[TBL] [Abstract][Full Text] [Related]
5. Optimum PSA reflex-range.
Benecchi L
Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
[TBL] [Abstract][Full Text] [Related]
6. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ
J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329
[TBL] [Abstract][Full Text] [Related]
7. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
[TBL] [Abstract][Full Text] [Related]
8. Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases.
Thiounn N; Saporta F; Flam TA; Pages F; Zerbib M; Vieillefond A; Martin E; Debré B; Chevillard S
Urology; 1997 Aug; 50(2):245-50. PubMed ID: 9255296
[TBL] [Abstract][Full Text] [Related]
9. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
Cama C; Olsson CA; Raffo AJ; Perlman H; Buttyan R; O'Toole K; McMahon D; Benson MC; Katz AE
J Urol; 1995 May; 153(5):1373-8. PubMed ID: 7536252
[TBL] [Abstract][Full Text] [Related]
10. High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels.
Obralic N; Kulovac B
Bosn J Basic Med Sci; 2011 Nov; 11(4):223-7. PubMed ID: 22117828
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease.
Devine PL; Walsh MD; McGuckin MA; Quin RJ; Hohn BG; Clague A; Samaratunga H
Int J Biol Markers; 1995; 10(4):221-5. PubMed ID: 8750649
[TBL] [Abstract][Full Text] [Related]
12. Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl.
Caglayan V; Onen E; Avci S; Sambel M; Kilic M; Oner S; Aydos MM; Yıldız HE
Arch Ital Urol Androl; 2019 Jan; 90(4):270-275. PubMed ID: 30655640
[TBL] [Abstract][Full Text] [Related]
13. Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
Demura T; Watarai Y; Togashi M; Hirano T; Ohashi N; Koyanagi T
J Urol; 1993 Nov; 150(5 Pt 2):1740-5. PubMed ID: 7692111
[TBL] [Abstract][Full Text] [Related]
14. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA.
Van Cangh PJ; De Nayer P; De Vischer L; Sauvage P; Tombal B; Lorge F; Wese FX; Opsomer R
Urology; 1996 Dec; 48(6A Suppl):67-70. PubMed ID: 8973703
[TBL] [Abstract][Full Text] [Related]
15. Prostate tissue and serum markers.
Mazzucchelli R; Colanzi P; Pomante R; Muzzonigro G; Montironi R
Adv Clin Path; 2000 Jul; 4(3):111-20. PubMed ID: 11080790
[TBL] [Abstract][Full Text] [Related]
16. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications.
Ghossein RA; Scher HI; Gerald WL; Kelly WK; Curley T; Amsterdam A; Zhang ZF; Rosai J
J Clin Oncol; 1995 May; 13(5):1195-200. PubMed ID: 7537803
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of free-to-total immunoreactive prostate-specific antigen ratios.
Wymenga LF; Duisterwinkel FJ; Groenier K; Visser-van Brummen P; Marrink J; Mensink HJ
Scand J Urol Nephrol; 2000 Jun; 34(3):181-7. PubMed ID: 10961472
[TBL] [Abstract][Full Text] [Related]
18. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
[TBL] [Abstract][Full Text] [Related]
19. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
[TBL] [Abstract][Full Text] [Related]
20. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]